IROXHEAL SLEEP GUMMIES
Testo originale in francese.
Prodotto naturale per la salute autorizzato in Canada
Se questo prodotto fosse venduto in Francia
- Conditions légales
Valeriana officinalis L.: L'absence de valépotriates doit être prouvée par des rapports d'analyse. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte | Massimo giornaliero, adulto |
|---|---|---|
| L-5-Hydroxytryptophane | 100 mg | Non calcolata |
| Valeriana officinalis Fonte : Valeriana officinalis - Racine Estratto : Matériel brut sec Rapporto di estrazione : 4:1 Equivalente di pianta secca : 1.200 mg | 300 mg | Non calcolata |
Ingredienti non medicinali
Acide citrique, Pectine, Maltose, Sucre, Eau purifiée, Cire de Carnauba
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
| Adultes | minimum : 18 ans | 2 Bloc | 1 Tous les jours |
Usi autorizzati in Canada
(Traditionally used in Herbal Medicine as a) sleep aid/(to) help(s) to promote sleep. Passiflora incarnata is traditionally used in Herbal Medicine as a sleep aid (during times of mental stress). Passiflora incarnata and Valeriana officinalis are traditionally used in Herbal Medicine to help relieve restlessness and/or nervousness (calmative). Helps (to) relieve sleep disturbances associated with mood imbalance. Helps (to) temporarily promote relaxation.
Testo originale in inglese.
Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Known Adverse Reactions : Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience skin hardening, pain or stiffness of muscles or joints, tremors, agitation/confusion, or an increased heart rate. Stop use if hypersensitivity/allergy occurs. When using this product you may experience gastrointestinal discomfort/disturbances.
Testo originale in inglese.
Cautions and Warnings : Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding. Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking carbidopa or health products with serotonergic activity such as mood balance supplements, cough medication containing dextromethorphan, pain killers or medications for nausea or migraine. Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia). Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia). Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen. When using this product avoid taking with alcohol or products that cause drowsiness. When using this product exercise caution if you drive or use machinery as you may experience drowsiness. When using this product exercise caution while driving or using machinery, as you may experience drowsiness.
Testo originale in inglese.
Contra-Indications : Do not use if you are taking antidepressants. Do not use if you have scleroderma.
Testo originale in inglese.
Scheda del prodotto
- Titolare
- Shenzhen Yunyou Feiyue Technology Co., Ltd.
- NPN o DIN-HM
- 80147881
- Stato
- Licenza attiva
- Data della licenza
- 16 marzo 2026
- Data di revisione
- Non indicata
- Forma
- Bloc
- Via di somministrazione
- Orale
- Tipo di domanda
- Officinale
Fonte
Scheda ufficiale Health Canada, licenza 80147881
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Testo originale in inglese.
Testo originale in francese.
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Avvertenze ufficiali (Health Canada)
Health Canada pubblica avvertenze su questi ingredienti:
- L-5-Hydroxytryptophane
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
5-HTP
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking carbidopa or health products with serotonergic activity such as mood balance supplements, cough medication containing dextromethorphan, pain killers or medications for nausea or migraine (Mayo Clinic Staff 2022; Patel and Marzella 2017; Turner et al 2006).
Fonti citate da Health Canada (3)
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Caso clinico
- Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Articolo di revisione
1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).
When using this product exercise caution while driving or using machinery, as you may experience drowsiness (Berardi et al. 2002).
Fonti citate da Health Canada (1)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollings CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condizione di applicazione: All uses (excluding weight management).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condizione di applicazione: Weight management.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Condizione di applicazione: Healthy mood balance; Fibromyalgia symptoms.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.
Controindicazioni
Condizione di applicazione: All uses.
Do not use if you have scleroderma (Lampert et al. 1992; Sternberg et al. 1980).
Fonti citate da Health Canada (2)
- Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Caso clinico
- Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Studio clinico
Do not use if you are taking antidepressants (Mayo Clinic Staff 2022; Patel and Marzella 2017).
Fonti citate da Health Canada (2)
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Caso clinico
1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).
Condizione di applicazione: Weight management.
Do not use if you are pregnant (HC 2010).
Fonti citate da Health Canada (2)
- HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
- SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf
Reazioni avverse note
When using this product you may experience gastrointestinal discomfort/disturbances (Turner et al. 2006; Byerley et al. 1987).
Fonti citate da Health Canada (2)
- Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology 1987;7(3):127-137. PubMed Studio clinico
- Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Articolo di revisione
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience skin hardening, pain or stiffness of muscles or joints, tremors, agitation/confusion, or an increased heart rate (Boyer 2023; Varga 2023; Mayo Clinic Staff 2022; Patel and Marzella 2017; Das et al. 2004; Erner et al. 2003; Lampert et al. 1992; Sternberg et al. 1980).
Fonti citate da Health Canada (8)
- Boyer EW. Serotonin syndrome (serotonin toxicity). UpToDate 2023 [Accessed 2023 October 18]. Available from: Available from : https://www.uptodate.com/.
- Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicology Letters 2004;150(1):111-122. PubMed Caso clinico
- Erner RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin Syndrome and Other Serotonergic Disorders. Pain Medicine 2003;4(1): 63-74.
- Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Caso clinico
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Caso clinico
- Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Studio clinico
- Varga J. Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate 2023 [Accessed 2023 October 18]. Available from : https://www.uptodate.com/.
1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).
- Valeriana officinalis
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
Valerian - VALERIANA OFFICINALIS
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).
Fonti citate da Health Canada (3)
- Barnes J, Anderson LA, Phillipson JD. Herbal Medicines: A guide for healthcare professionals. 2nd ed. London (UK): Pharmaceutical Press; 2002.
- Blumenthal M, Hall T, Goldberg A, Kunz T, Dinda K, Brinckmann J, Wollschlaeger B, editors. 2003. The ABC Clinical Guide to Herbs: Valerian. Austin, Texas: American Botanical Council.
- Mills E, Dugoua J, Perri D, Koren G. 2006. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (GB): Taylor and Francis Medical.
When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).
Fonti citate da Health Canada (2)
- Gennaro AR, Marderosian AHD, Hanson GR, Medwick T, editors. 2000. Remington: The Science and Practice of Pharmacy, 20th edition. Philadelphia (PA): Lippincott Williams & Wilkins.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications. 2010.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).
Fonti citate da Health Canada (3)
- Bradley PR, editor. 1992. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
- EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Condizione di applicazione: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).
Fonti citate da Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 2002. Pharmacotherapy: A Pathophysiologic Approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.
- EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf
Condizione di applicazione: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.
La data della prova di questo elenco di ingredienti è sconosciuta.
Il prodotto è cambiato? Fotografi la confezione.
Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.